Service notifications for recommended Technology Appraisals (TAs)
Technology Appraisals are listed below in alphanumerical order with links to further information on the NICE website.
| Title | Description | Date added | Download |
|---|---|---|---|
| TA1114 | Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | 20-02-2026 | DownloadPreview |
| TA1113 | Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma | 19-02-2026 | DownloadPreview |
| TA1110 | Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer (review of TA721) | 19-02-2026 | DownloadPreview |
| TA1087 | Service Notification Betula verrucose for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen | 19-02-2026 | DownloadPreview |
| TA1066 | Service Notification Somapacitan for treating hormone deficiency in people 3 to 17 years | 19-02-2026 | DownloadPreview |
| TA1109 | Service Notification Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | 17-02-2026 | DownloadPreview |
| TA1103 (review of TA909) | Service Notification Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor (review of TA909) | 13-02-2026 | DownloadPreview |
| TA1101 | Service Notification Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over | 13-02-2026 | DownloadPreview |
| TA1075 (review of TA775) | Dapagliflozin for treating chronic kidney disease | 09-02-2026 | DownloadPreview |
| TA1099 | Service Notification Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy | 09-02-2026 | DownloadPreview |
| TA1097 | Service Notification Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy | 09-02-2026 | DownloadPreview |
| TA1096 | Service Notification Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis | 09-02-2026 | DownloadPreview |
| TA1095 | Service Notification Guselkumab for previously treated moderately to severely active Crohn's disease | 09-02-2026 | DownloadPreview |
| TA1094 | Service Notification Guselkumab for treating moderately to severely active ulcerative colitis | 09-02-2026 | DownloadPreview |
| TA1098 | Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable | 09-02-2026 | DownloadPreview |
| TA1093 | Idebenone for treating visual impairment in Lebers hereditary optic neuropathy in people 12 years and over | 09-02-2026 | DownloadPreview |
| TA1045 (review of TA834) | Service Notification 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites | 09-02-2026 | DownloadPreview |
| TA1067 | Service Notification Linzagolix for treating symptoms of endometriosis | 09-02-2026 | DownloadPreview |
| TA1090 | Service Notification Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma | 09-02-2026 | DownloadPreview |
| TA1092 | Service Notification Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer | 09-02-2026 | DownloadPreview |